AWM
BCLI

Able Wealth Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Able Wealth Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-128
Closed -$524 – 138
2023
Q4 		$524 Buy
+128
New +$384 ﹤0.01% 551

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Able Wealth Management's BCLI Position: Q1 2024 in Review

Able Wealth Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2024, closing a stake of 128 shares — an estimated $524 sold.

Able Wealth Management first reported a position in BCLI in Q4 2023 and held it in 1 quarter. The position peaked at $524 in Q4 2023. 47 funds tracked by Wall St. Rank hold BCLI as of Q1 2024.

  • Able Wealth Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2024 after selling out during the quarter.
  • Able Wealth Management sold 128 BRAINSTORM CELL THERAPUTC shares in Q1 2024, an estimated $524.
  • Able Wealth Management first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2023 and held it in 1 quarter.
  • Able Wealth Management's BRAINSTORM CELL THERAPUTC position peaked at $524 in Q4 2023.
  • 47 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2024.

Based on Able Wealth Management's 13F filing for Q1 2024, filed 1 Nov 2024.